User menu

Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.

Bibliographic reference Ianotto, Jean-Christophe ; Boyer-Perrard, Françoise ; Gyan, Emmanuel ; Laribi, Kamel ; Cony-Makhoul, Pascale ; et. al. Efficacy and safety of pegylated-interferon α-2a in myelofibrosis: a study by the FIM and GEM French cooperative groups.. In: British journal of haematology, Vol. 162, no.6, p. 783-791 (2013)
Permanent URL http://hdl.handle.net/2078.1/141287
  1. Barbui Tiziano, Barosi Giovanni, Birgegard Gunnar, Cervantes Francisco, Finazzi Guido, Griesshammer Martin, Harrison Claire, Hasselbalch Hans Carl, Hehlmann Rudiger, Hoffman Ronald, Kiladjian Jean-Jacques, Kröger Nicolaus, Mesa Ruben, McMullin Mary F., Pardanani Animesh, Passamonti Francesco, Vannucchi Alessandro M., Reiter Andreas, Silver Richard T., Verstovsek Srdan, Tefferi Ayalew, Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet, 10.1200/jco.2010.31.8436
  2. Barosi Giovanni, Rosti Vittorio, Vannucchi Alessandro M, Therapeutic approaches in myelofibrosis, 10.1517/14656566.2011.568939
  3. Begna K H, Mesa R A, Pardanani A, Hogan W J, Litzow M R, McClure R F, Tefferi A, A phase-2 trial of low-dose pomalidomide in myelofibrosis, 10.1038/leu.2010.254
  4. Cervantes F., Dupriez B., Pereira A., Passamonti F., Reilly J. T., Morra E., Vannucchi A. M., Mesa R. A., Demory J.-L., Barosi G., Rumi E., Tefferi A., New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment, 10.1182/blood-2008-07-170449
  5. Cervantes Francisco, Dupriez Brigitte, Passamonti Francesco, Vannucchi Alessandro M., Morra Enrica, Reilly John T., Demory Jean-Loup, Rumi Elisa, Guglielmelli Paola, Roncoroni Elisa, Tefferi Ayalew, Pereira Arturo, Improving Survival Trends in Primary Myelofibrosis: An International Study, 10.1200/jco.2012.42.0240
  6. Deeg H. J., Appelbaum F. R., Indications for and current results with allogeneic hematopoietic cell transplantation in patients with myelofibrosis, 10.1182/blood-2011-04-349142
  7. Dupriez, Blood, 88, 1013 (1996)
  8. Emanuel Robyn M., Dueck Amylou C., Geyer Holly L., Kiladjian Jean-Jacques, Slot Stefanie, Zweegman Sonja, te Boekhorst Peter A.W., Commandeur Suzan, Schouten Harry C., Sackmann Federico, Kerguelen Fuentes Ana, Hernández-Maraver Dolores, Pahl Heike L., Griesshammer Martin, Stegelmann Frank, Doehner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N., Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L., Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M., Passamonti Francesco, Andreasson Bjorn, Ferarri Maria L., Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Tefferi Ayalew, Mesa Ruben A., Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs, 10.1200/jco.2012.42.3863
  9. Gale R.P., Barosi G., Barbui T., Cervantes F., Dohner K., Dupriez B., Gupta V., Harrison C., Hoffman R., Kiladjian J.-J., Mesa R., Mc Mullin M.F., Passamonti F., Ribrag V., Roboz G., Saglio G., Vannucchi A., Verstovsek S., What are RBC-transfusion-dependence and -independence?, 10.1016/j.leukres.2010.07.015
  10. Gangat Naseema, Caramazza Domenica, Vaidya Rakhee, George Geeta, Begna Kebede, Schwager Susan, Van Dyke Daniel, Hanson Curtis, Wu Wenting, Pardanani Animesh, Cervantes Francisco, Passamonti Francesco, Tefferi Ayalew, DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates Prognostic Information From Karyotype, Platelet Count, and Transfusion Status, 10.1200/jco.2010.32.2446
  11. Gowin K., Thapaliya P., Samuelson J., Harrison C., Radia D., Andreasson B., Mascarenhas J., Rambaldi A., Barbui T., Rea C. J., Camoriano J., Gentry A., Kiladjian J.-J., O'Connell C., Mesa R., Experience with pegylated interferon  -2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients, 10.3324/haematol.2011.061390
  12. Harrison Claire, Kiladjian Jean-Jacques, Al-Ali Haifa Kathrin, Gisslinger Heinz, Waltzman Roger, Stalbovskaya Viktoriya, McQuitty Mari, Hunter Deborah S., Levy Richard, Knoops Laurent, Cervantes Francisco, Vannucchi Alessandro M., Barbui Tiziano, Barosi Giovanni, JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis, 10.1056/nejmoa1110556
  13. Hasselbalch Hans Carl, Kiladjian Jean-Jacques, Silver Richard T., Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms, 10.1200/jco.2011.35.6238
  14. Ianotto Jean-Christophe, Kiladjian Jean-Jacques, Demory Jean-Louis, Roy Lydia, Boyer Françoise, Rey Jerôme, Dupriez Brigitte, Berthou Christian, Abgrall Jean-François, PEG-IFN-α-2a therapy in patients with myelofibrosis, 10.1111/j.1365-2141.2009.07745.x
  15. Jabbour Elias, Kantarjian Hagop, Cortes Jorge, Thomas Deborah, Garcia-Manero Guillermo, Ferrajoli Alessandra, Faderl Stefan, Richie Mary Ann, Beran Miloslav, Giles Francis, Verstovsek Srdan, PEG-IFN-α-2b therapy in BCR-ABL–negative myeloproliferative disorders : Final Result of a Phase 2 Study, 10.1002/cncr.23018
  16. Jabbour E., Thomas D., Kantarjian H., Zhou L., Pierce S., Cortes J., Verstovsek S., Comparison of thalidomide and lenalidomide as therapy for myelofibrosis, 10.1182/blood-2010-12-325589
  17. Kiladjian J.-J., Cassinat B., Chevret S., Turlure P., Cambier N., Roussel M., Bellucci S., Grandchamp B., Chomienne C., Fenaux P., Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, 10.1182/blood-2008-03-143537
  18. Kiladjian J.-J., Mesa R. A., Hoffman R., The renaissance of interferon therapy for the treatment of myeloid malignancies, 10.1182/blood-2010-08-258772
  19. Lissandre S, Bay J-O, Cahn J-Y, Porcher R, Cacheux V, Cabrespine A, Cornillon J, Cassinat B, Peffault de Latour R, Socie G, Robin M, Retrospective study of allogeneic haematopoietic stem-cell transplantation for myelofibrosis, 10.1038/bmt.2010.276
  20. Marchetti Monia, Barosi Giovanni, Balestri Francesca, Viarengo Gianluca, Gentili Sara, Barulli Sara, Demory Jean-Loup, Ilariucci Fiorella, Volpe Antonio, Bordessoule Dominique, Grossi Alberto, Le Bousse-Kerdiles Marie Caroline, Caenazzo Andrea, Pecci Alessandro, Falcone Antonietta, Broccia Giorgio, Bendotti Cesarina, Bauduer Fredric, Buccisano Francesco, Dupriez Brigitte, Low-Dose Thalidomide Ameliorates Cytopenias and Splenomegaly in Myelofibrosis With Myeloid Metaplasia: A Phase II Trial, 10.1200/jco.2004.08.160
  21. Mesa Ruben A., Transplantation for myelofibrosis: Time for a randomized trial, 10.1016/j.leukres.2011.03.005
  22. Mesa R. A., Yao X., Cripe L. D., Li C. Y., Litzow M., Paietta E., Rowe J. M., Tefferi A., Tallman M. S., Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903, 10.1182/blood-2010-05-287417
  23. Nguyen, Hematology of American Society of Hematology Education Program, 2012, 567 (2012)
  24. Pardanani Animesh, Gotlib Jason R., Jamieson Catriona, Cortes Jorge E., Talpaz Moshe, Stone Richard M., Silverman Michael H., Gilliland D. Gary, Shorr Jolene, Tefferi Ayalew, Safety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis, 10.1200/jco.2010.32.8021
  25. Parmeggiani L., Ferrant A., Rodhain J., Michaux J. L., Sokal G., Alpha interferon in the treatment of symptomatic myelofibrosis with myeloid metaplasia, 10.1111/j.1600-0609.1987.tb00762.x
  26. Passamonti F., Cervantes F., Vannucchi A. M., Morra E., Rumi E., Pereira A., Guglielmelli P., Pungolino E., Caramella M., Maffioli M., Pascutto C., Lazzarino M., Cazzola M., Tefferi A., A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment), 10.1182/blood-2009-09-245837
  27. Quintás-Cardama Alfonso, Kantarjian Hagop, Manshouri Taghi, Luthra Rajyalakshmi, Estrov Zeev, Pierce Sherry, Richie Mary Ann, Borthakur Gautam, Konopleva Marina, Cortes Jorge, Verstovsek Srdan, Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia Vera, 10.1200/jco.2009.23.6075
  28. Silver R. T., Vandris K., Goldman J. J., Recombinant interferon-  may retard progression of early primary myelofibrosis: a preliminary report, 10.1182/blood-2010-11-320069
  29. Swerdlow, WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 2 (2008)
  30. Tefferi Ayalew, Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management, 10.1002/ajh.22210
  31. Tefferi A., How I treat myelofibrosis, 10.1182/blood-2010-11-315614
  32. Tefferi A., International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT), 10.1182/blood-2006-03-009746
  33. Verstovsek Srdan, Kantarjian Hagop, Mesa Ruben A., Pardanani Animesh D., Cortes-Franco Jorge, Thomas Deborah A., Estrov Zeev, Fridman Jordan S., Bradley Edward C., Erickson-Viitanen Susan, Vaddi Kris, Levy Richard, Tefferi Ayalew, Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis, 10.1056/nejmoa1002028
  34. Verstovsek Srdan, Mesa Ruben A., Gotlib Jason, Levy Richard S., Gupta Vikas, DiPersio John F., Catalano John V., Deininger Michael, Miller Carole, Silver Richard T., Talpaz Moshe, Winton Elliott F., Harvey Jimmie H., Arcasoy Murat O., Hexner Elizabeth, Lyons Roger M., Paquette Ronald, Raza Azra, Vaddi Kris, Erickson-Viitanen Susan, Koumenis Iphigenia L., Sun William, Sandor Victor, Kantarjian Hagop M., A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis, 10.1056/nejmoa1110557
  35. Wadleigh Martha, Tefferi Ayalew, Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria, 10.1007/s12185-010-0529-5